No Additional Heparin During Dialysis for Patients on Eliquis
A dialysis patient already taking apixaban (Eliquis) twice daily should NOT routinely receive additional heparin bolus and hourly infusion during dialysis treatments. The patient is already systemically anticoagulated, and adding heparin significantly increases bleeding risk without clear benefit.
Key Evidence and Rationale
Apixaban Provides Adequate Systemic Anticoagulation
The FDA label for Eliquis explicitly addresses dialysis patients, noting that "administration of ELIQUIS at the usually recommended dose will result in concentrations of apixaban and pharmacodynamic activity similar to those observed in the ARISTOTLE study" 1. While the FDA acknowledges uncertainty about stroke reduction in this population, the drug clearly provides systemic anticoagulation.
Dialysis has minimal impact on apixaban clearance - only about 4% of the drug is removed during a dialysis session 2, and dialysis clearance is approximately 18 mL/min 1. This means apixaban levels remain therapeutic throughout dialysis, providing circuit anticoagulation.
Bridging Anticoagulation Is Not Recommended
Multiple guidelines explicitly state that bridging with parenteral anticoagulation (UFH or LMWH) is NOT recommended for patients on direct oral anticoagulants undergoing procedures 3. The French GIHP guidelines specifically state: "preoperative bridging by UFH or LMWH is not recommended" for patients on DOACs 3.
This principle extends to dialysis - adding heparin to a patient already on apixaban constitutes unnecessary dual anticoagulation.
Safety Data Supports Heparin Avoidance
A large retrospective study found that heparin use during dialysis in patients on systemic anticoagulants showed no additional safety benefit and that "the decision to withhold heparin should not solely be based upon the concurrent use of anticoagulant or antiplatelet agents" 4. However, this study actually found heparin was safe when added - but the key point is that it wasn't necessary for circuit patency when systemic anticoagulation was present.
The 2019 AHA/ACC/HRS guidelines note that dialysis patients have increased bleeding risk 5, 6, 5, and apixaban already provides lower bleeding rates than warfarin in this population 5.
Practical Management Approach
Standard Protocol
- Continue apixaban at prescribed dose (typically 2.5 mg or 5 mg twice daily based on patient characteristics)
- No heparin bolus or infusion during dialysis
- Monitor circuit for clotting (rare with therapeutic apixaban levels)
- Use saline flushes as needed for circuit maintenance
Timing Considerations
Recent pharmacokinetic data shows that timing of apixaban relative to dialysis affects drug exposure 7. A 2.5 mg dose post-dialysis provides similar exposure to 5 mg pre-dialysis 7. However, for circuit anticoagulation purposes, the patient should have therapeutic levels regardless of timing.
When Heparin Might Be Considered
The only scenario where additional anticoagulation might be discussed is if:
- Circuit clotting occurs despite therapeutic apixaban levels (extremely rare)
- Patient has documented subtherapeutic apixaban levels
- Specific high-risk dialysis access or circuit issues exist
Even then, regional citrate anticoagulation would be preferable to systemic heparin to avoid compounding bleeding risk 8.
Critical Caveats
Bleeding risk is the primary concern. The RENAL-AF trial showed 1-year major or clinically relevant non-major bleeding rates of 32% in apixaban-treated dialysis patients 9. Adding heparin would only increase this risk.
Circuit patency is maintained by systemic apixaban. Studies show apixaban concentrations remain in therapeutic range throughout dialysis 10, 2, with anti-Xa activity correlating strongly with apixaban levels 10.
Avoid the outdated practice of routine heparin for all dialysis patients. This approach fails to account for patients already on systemic anticoagulation and unnecessarily increases hemorrhagic complications.
The evidence clearly supports continuing apixaban alone without additional heparin during dialysis treatments, prioritizing patient safety by avoiding dual anticoagulation and its associated bleeding risks.